|
Market Closed -
NSE India S.E.
19:05:07 18/09/2026 HKT
|
5-day change | 1st Jan Change | ||
| 5,466.50 INR | +2.21% |
|
+7.45% | -0.73% |
| 09-08 | Alkem Laboratories Limited Launches Renocia Exo, India?s First Patented Ginsenoside Exosome-Based Hair Growth Serum | CI |
| 08-14 | Alkem Laboratories Limited, Q1 2027 Earnings Call, Aug 14, 2026 |
Company Valuation: Alkem Laboratories Limited
Data adjusted to current consolidation scope
| Fiscal Period: March | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 432,909 | 406,055 | 590,890 | 583,680 | 633,575 | 653,602 | - | - |
| Change | - | -6.2% | 45.52% | -1.22% | 8.55% | 3.16% | - | - |
| Enterprise Value (EV) 1 | 433,805 | 393,853 | 587,236 | 578,678 | 632,481 | 640,523 | 625,544 | 616,741 |
| Change | - | -9.21% | 49.1% | -1.46% | 9.3% | 1.27% | -2.34% | -1.41% |
| P/E | 26.3x | 41.3x | 32.9x | 27x | 27.5x | 28.5x | 24.8x | 21.4x |
| PBR | 5.01x | 4.49x | 5.73x | 4.87x | 4.58x | 4.23x | 3.74x | 3.3x |
| PEG | - | -1x | 0.4x | 1.3x | 4.37x | -97.74x | 1.7x | 1.3x |
| Capitalization / Revenue | 4.07x | 3.5x | 4.66x | 4.5x | 4.31x | 3.91x | 3.52x | 3.19x |
| EV / Revenue | 4.08x | 3.4x | 4.64x | 4.46x | 4.3x | 3.84x | 3.37x | 3.01x |
| EV / EBITDA | 21.1x | 24.5x | 26.2x | 23x | 21x | 18.7x | 15.9x | 13.9x |
| EV / EBIT | 24.8x | 30.3x | 30.2x | 26.9x | 24.1x | 21.5x | 18.3x | 15.8x |
| EV / FCF | 55.4x | 27.1x | 33.3x | 45.3x | 42.8x | 62.3x | 30.6x | 24.2x |
| FCF Yield | 1.81% | 3.69% | 3% | 2.21% | 2.33% | 1.61% | 3.27% | 4.14% |
| Dividend per Share 2 | 34 | 25 | 40 | 45 | 53 | 49.33 | 55.28 | 63.37 |
| Rate of return | 0.94% | 0.74% | 0.81% | 0.92% | 1% | 0.9% | 1.01% | 1.16% |
| EPS 2 | 137.6 | 82.31 | 150.2 | 181.1 | 192.5 | 191.9 | 220.7 | 256 |
| Distribution rate | 24.7% | 30.4% | 26.6% | 24.8% | 27.5% | 25.7% | 25% | 24.8% |
| Net sales 1 | 106,342 | 115,993 | 126,676 | 129,645 | 147,123 | 166,997 | 185,721 | 204,703 |
| EBITDA 1 | 20,529 | 16,094 | 22,455 | 25,122 | 30,052 | 34,213 | 39,286 | 44,365 |
| EBIT 1 | 17,490 | 12,990 | 19,462 | 21,550 | 26,232 | 29,727 | 34,232 | 39,074 |
| Net income 1 | 16,456 | 9,842 | 17,958 | 21,655 | 23,018 | 23,143 | 27,153 | 31,030 |
| Net Debt 1 | 896.1 | -12,202 | -3,654 | -5,003 | -1,094 | -13,079 | -28,058 | -36,861 |
| Reference price 2 | 3,620.70 | 3,396.10 | 4,942.00 | 4,881.70 | 5,299.00 | 5,466.50 | 5,466.50 | 5,466.50 |
| Nbr of stocks (in thousands) | 119,565 | 119,565 | 119,565 | 119,565 | 119,565 | 119,565 | - | - |
| Announcement Date | 13/5/22 | 19/5/23 | 29/5/24 | 29/5/25 | 28/5/26 | - | - | - |
1INR in Million2INR
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 28.48x | 3.84x | 18.72x | 0.9% | 6.81B | |
| 32.78x | 11.92x | 24.16x | 0.6% | 1,028B | |
| 30.03x | 6.68x | 18.7x | 1.99% | 651B | |
| 33.38x | 7.81x | 16.15x | 2.6% | 466B | |
| 19.33x | 4.72x | 11.71x | 2.81% | 346B | |
| 19.72x | 5.16x | 12.79x | 3.11% | 266B | |
| 21.26x | 4.42x | 12.58x | 1.99% | 259B | |
| 24.43x | 6.42x | 11.43x | 2.62% | 208B | |
| 12.52x | 4.56x | 9.46x | 4.01% | 191B | |
| -45.4x | 6.61x | 25.81x | 2.19% | 186B | |
| Average | 17.65x | 6.21x | 16.15x | 2.28% | 360.85B | |
| Weighted average by Cap. | 23.69x | 7.72x | 17.84x | 1.99% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- ALKEM Stock
- Valuation Alkem Laboratories Limited
Select your edition
All financial news and data tailored to specific country editions
